Search results
Why selling to Novartis made sense for Mariana
BioPharma Dive via Yahoo Finance· 5 hours agoNovartis’ success with Pluvicto in prostate cancer has motivated others, Mariana among them, to follow into the field. “We began thinking in mid-2020...
Prostate cancer: Supplement, keto diet may boost immunotherapy
Medical News Today· 1 day agoAbout 13% of cisgender men around the world will receive a prostate cancer diagnosis in their...
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical...
WKBN 27 Youngstown· 55 minutes agoJohnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT ...
Angle to Develop Prostate Cancer Liquid Biopsy Assay for AstraZeneca
GenomeWeb News· 4 hours agoAngle announced on Friday that it has signed a supplier agreement with AstraZeneca to develop an androgen receptor (AR) assay to assess prostate cancer ...
Swing Against Cancer 2024 breaks records, raises $220,000 for research
The Desert Sun via Yahoo News· 10 hours agoAfter presenting an engaging audience participation exercise about statistics in cancer research and...
New Trials in Prostate Cancer: Could Your Patient Benefit?
Medscape· 5 days agoPerhaps one of your patients could benefit from a clinical trial that has recently opened in ...
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032
WKBN 27 Youngstown· 1 hour agoAccording to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by ...
Angle PLC Announces New Commercial Agreement with Large Pharma
Digital Journal· 11 hours agoANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies GUILDFORD, SURREY / ACCESSWIRE / May ...
Trelstar dosage: Form, strengths, how to use, and more
Medical News Today· 2 days agoTrelstar (triptorelin pamoate) is a brand-name drug that’s prescribed for advanced prostate cancer...
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk...
WTRF Wheeling· 2 hours ago"The high complete response rate and durability of these responses observed in patients treated with TAR-200 underscores the potential of this treatment approach for patients...
